Trial Profile
A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 11 Jan 2024
Price :
$35
*
At a glance
- Drugs AZD 5069 (Primary) ; Danvatirsen (Primary) ; Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Head and neck cancer; Prostate cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms SCORES
- Sponsors AstraZeneca
- 15 Dec 2023 Planned End Date changed from 29 Dec 2023 to 16 Mar 2025.
- 03 Oct 2022 Planned End Date changed from 21 Sep 2022 to 29 Dec 2023.
- 27 Oct 2021 Planned End Date changed from 2 Sep 2021 to 21 Sep 2022.